Cardiac Hormones Activate ERK 1/2 Kinases in Human Fibroblasts

Abstract

Two cardiac hormones, vessel dilator and kaliuretic peptide, localize to fibroblasts with immunohistochemistry. Vessel dilator and kaliuretic peptide were investigated in dose-response and time-sequenced experiments for their cell signaling of extracellular signal–regulated kinases 1/2 in human fibroblasts to test the hypothesis that these two cardiovascular hormones contribute to fibroblast proliferation by activating extracellular signal–regulated kinases 1/2. Vessel dilator at 10 pM (physiological range) enhanced the phosphorylation of extracellular signal–regulated kinases 1/2 by 188±9% (p<0.001) in 10 min and, maximally, by 200±10% in 15 min (p<0.001). Vessel dilator at 10 nM enhanced the phosphorylation of extracellular signal–regulated kinases 1/2 by 107±5% (p<0.01) in 10 min. Kaliuretic peptide at 10 pM enhanced the activation of extracellular signal–regulated kinases 1/2 by 389±19% in 10 min (p<0.001). Kaliuretic peptide at 10 nM enhanced the phosphorylation of extracellular signal–regulated kinases 1/2 by 82±4% (p<0.01). Our results show that both cardiac hormones activate extracellular signal–regulated kinases 1/2 in human fibroblasts, suggesting that they may have a role in enhancing fibroblast proliferation.

natriuretic peptides - cell signaling - cardiac remodeling - proliferation

References

• 1 Pages G, Lenormand P, L’Allemain G, Chambard JC, Meloche S, Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation.  Proc Natl Acad Sci USA. 1993;  90 8319-8323
• 2 Davis RJ. The mitogen-activated protein kinase signal transduction pathway.  J Biol Chem. 1993;  268 14553-14556
• 3 Cobb MH, Goldsmith EJ. How MAP kinases are regulated.  J Biol Chem. 1995;  270 14843-14846
• 4 Sugden PH, Clerk A. Regulation of mitogen-activated protein kinase cascades in the heart.  Adv Enzyme Regul. 1998;  38 87-98
• 5 Utsugi M, Dobashi K, Ishizuka T, Masubuchi K, Shimizu Y, Nakazawa T, Mori M. C-Jun-NH₂-Terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-β1 in human lung fibroblasts.  Am J Respir Cell Mol Biol. 2003;  28 754-761
• 6 Raffetto JD, Vasquez R, Goodwin DG, Menzoian JO. Mitogen-activated protein kinase pathway regulates cell proliferation in venous ulcer fibroblasts.  Vasc Endovascular Surg. 2006;  40 59-66
• 7 Vesely DL. Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression.  IUBMB Life. 2002;  53 153-159
• 8 Vesely DL. Natriuretic hormones. In: R. J. Alpern, S. C. Herbert, eds. Seldin and Giebisch's The Kidney: Physiology and Pathophysiology. 4th edition. Elsevier Inc. 2007: 947-977
• 9 Saba SR, Garces AH, Clark LC, Soto J, Gower Jr WR, Vesely DL. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas.  J Histochem Cytochem. 2005;  53 989-995
• 10 Saba SR, Vesely DL. Cardiac natriuretic peptides: Hormones with anticancer effects that localize to nucleus, cytoplasm, endothelium and fibroblasts of human cancers.  Histology & Histopathology. 2006;  21 775-783
• 11 Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure.  Circulation. 1989;  80 438-449
• 12 Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators.  Cardiovascular Res. 1997;  36 246-255
• 13 Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease.  Scan J Clin Lab Invest. 1998;  58 205-216
• 14 Oliver PM, Fox JE, Kim R, Rockman HA, Kim H-S, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A.  Proc Natl Acad Sci. 1997;  94 14730-14735
• 15 Bubikat A, Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, Gödecke A, Baba HA, Kuhn M. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice.  J Biol Chem. 2005;  280 21594-21599
• 16 Franco V, Chen Y-F, Oparil S, Feng JA, Wang D, Hage F, Perry G. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling.  Hypertension. 2004;  44 746-750
• 17 Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M, Nakao K. Cardiac fibrosis in mice lacking brain natriuretic peptide.  Proc Natl Acad Sci. 2000;  97 4239-4244
• 18 Ogawa Y, Tamura N, Chusho H, Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart.  Can J Physiol Pharmacol. 2001;  79 723-729
• 19 Horio T, Tokudome T, Maki T, Yoshihara F, Suga S-I, Nishikimi T, Kojima M, Kawano Y, Kangawa K. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts.  Endocrinology. 2003;  144 2279-2284
• 20 Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells.  Anticancer Res. 2006;  26 3217-3222

Correspondence